doi:https://doi.org/

References:

Pennlert J., Asplund K., Carlberg B., et al. Antithrombotic treatment following intracerebral hemorrhage in patients with and without atrial fibrillation. Stroke 2015;46:2094—2099.
Hacke W. The dilemma of reinstituting anticoagulation for patients with cardioembolic sources and intracranial hemorrhage: how wide is the strait between Skylla and Karybdis? Arch Neurol 2000;57:1682—1684.
Rabinstein A.A., Gupta A. Restarting anticoagulation after intracranial hemorrhage: a risky decision with no recipe. Neurology. 2014;82:1016—1017.
Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke 2011;42:3661—3662.
Schulman S. Resumption of oral anticoagulation after warfarin-asso- ciated intracerebral hemorrhage: no. Stroke 2011;42:3663—3664.
Pennlert J., Eriksson M., Carlberg B., Wiklund P.G. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke 2014;45:1839—1841.
Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500—1510.
Nielsen P.B., Larsen T.B., Skjøth F., et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 2015;132:517—525.
Ottosen T.P., Grijota M., Hansen M.L., et al. Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke 2016;47:1837—1843.
Steiner T., Al-Shahi Salman R., Beer R., et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014;9:840—855.
Hemphill J.C. 3rd, Greenberg S.M., Anderson C.S., et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015;46:2032—2060.
Riksstroke. Riksstroke årsrapport 2014 (annual report 2014). http:// www.riksstroke.org/wp-content/uploads/2015/12/Strokerapport_AKUT- TIA_LR.pdf. Accessed January 19, 2016.
Wettermark B., Hammar N.., Fored C.M., et al. The new Swedish Prescribed Drug Register — opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726—735.
Ludvigsson J.F., Andersson E., Ekbom A., et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
Statistics Sweden. Longitudinell integrationsdatabas för hälsoförsäkrings- och arbetsmarknadsstudier (LISA) (longitudinal integration database for Health Insurance and Labour Market Studies). http:// www.Scb.Se/lisa. Accessed December 03, 2014.
National Board of Health and Welfare. Dödsorsaksregistret(Cause of Death Registry). http://www.socialstyrelsen.se/register/dodsorsaksregistret. Accessed January 19, 2016.
van Nieuwenhuizen K.M., van der Worp H.B., Algra A., et al; APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials 2015;16:393.
Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263—272.
Majeed A., Kim Y.K., Roberts R.S., et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010;41:2860—2866.
Hawryluk G.W., Austin J.W., Furlan J.C., et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 2010;8:1500—1508.
Staerk L., Lip G.Y., Olesen J.B., et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015;351:h5876.
Apostolakis S., Lane D.A., Buller H., Lip G.Y. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost 2013;110:1074—1079.
Viswanathan A., Rakich S.M., Engel C., et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006;66:206—209.
Köster M., Asplund K., Johansson Å., Stegmayr B. Refinement of Swedish administrative registers to monitor stroke events on the national level. Neuroepidemiology 2013;40:240—246.